If this is your first visit, be sure to check out the FAQ in HCMA Announcements. You may have to register before you can post: click the register link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below. Your Participation in this message board is strictly voluntary. Information and comments on the message board do not necessarily reflect the feelings, opinions, or positions of the Hypertrophic Cardiomyopathy Association. At no time should participants to this board substitute information within for individual medical advice. The Hypertrophic Cardiomyopathy Association shall not be liable for any information provided herein. All participants in this board should conduct themselves in a professional and respectful manner. Failure to do so will result in suspension or termination. The moderators of the message board working with the HCMA will be responsible for notifying participants if they have violated the rules of conduct for the board. Moderators or HCMA staff may edit any post to ensure it conforms with the rules of the board or may delete it. This community is welcoming to all those with HCM we ask that you remember each user comes to the board with information and a point of view that may differ from that which you hold, respect is critical, please post respectfully. Thank you

Announcement

Collapse
No announcement yet.

12 different journals talk about ICD's in HCM!

Collapse

About the Author

Collapse

Lisa Salberg Find out more about Lisa Salberg
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • 12 different journals talk about ICD's in HCM!

    1 of 12 DOCUMENTS

    Copyright 2004 Cardiovascular Device Liability Week via LawRx.com via NewsRx.com
    and NewsRx.net
    Cardiovascular Device Liability Week

    July 4, 2004

    SECTION: EXPANDED REPORTING; Pg. 20

    LENGTH: 240 words

    HEADLINE: CENTENARY INSTITUTE, NEWTOWN;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Cardiovascular Device Liability Week editors
    from staff and other reports. Copyright 2004, Cardiovascular Device Liability
    Week via LawRx.com.

    LOAD-DATE: June 25, 2004

    2 of 12 DOCUMENTS

    Copyright 2004 Heart Disease Weekly via NewsRx.com & NewsRx.net
    Heart Disease Weekly

    July 4, 2004

    SECTION: EXPANDED REPORTING; Pg. 23

    LENGTH: 237 words

    HEADLINE: CARDIOVASCULAR DISEASE;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Heart Disease Weekly editors from staff and
    other reports. Copyright 2004, Heart Disease Weekly via NewsRx.com &
    NewsRx.net.

    LOAD-DATE: June 25, 2004

    3 of 12 DOCUMENTS

    Copyright 2004 Medical Devices & Surgical Technology Week via NewsRx.com &
    NewsRx.net
    Medical Devices & Surgical Technology Week

    July 4, 2004

    SECTION: EXPANDED REPORTING; Pg. 45

    LENGTH: 245 words

    HEADLINE: CARDIOVASCULAR DISEASE;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Medical Devices & Surgical Technology Week
    editors from staff and other reports. Copyright 2004, Medical Devices &
    Surgical Technology Week via NewsRx.com & NewsRx.net.

    LOAD-DATE: June 25, 2004

    4 of 12 DOCUMENTS

    Copyright 2004 Healthcare Mergers, Acquisitions & Ventures Week via IncRx.com
    via NewsRx.com and NewsRx.net
    Healthcare Mergers, Acquisitions & Ventures Week

    July 3, 2004

    SECTION: EXPANDED REPORTING; Pg. 25

    LENGTH: 245 words

    HEADLINE: CENTENARY INSTITUTE, NEWTOWN;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Healthcare Mergers, Acquisitions & Ventures
    Week editors from staff and other reports. Copyright 2004, Healthcare Mergers,
    Acquisitions & Ventures Week via IncRx.com.

    LOAD-DATE: June 25, 2004

    5 of 12 DOCUMENTS

    Copyright 2004 Obesity, Fitness & Wellness Week via NewsRx.com & NewsRx.net
    Obesity, Fitness & Wellness Week

    July 3, 2004

    SECTION: EXPANDED REPORTING; Pg. 199

    LENGTH: 242 words

    HEADLINE: CARDIOVASCULAR DISEASE;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Obesity, Fitness & Wellness Week editors from
    staff and other reports. Copyright 2004, Obesity, Fitness & Wellness Week via
    NewsRx.com & NewsRx.net.

    LOAD-DATE: June 25, 2004

    6 of 12 DOCUMENTS

    Copyright 2004 Biotech Law Weekly via LawRx.com via NewsRx.com and NewsRx.net
    Biotech Law Weekly

    July 2, 2004

    SECTION: EXPANDED REPORTING; Pg. 41

    LENGTH: 234 words

    HEADLINE: CENTENARY INSTITUTE, NEWTOWN;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Biotech Law Weekly editors from staff and other
    reports. Copyright 2004, Biotech Law Weekly via LawRx.com.

    LOAD-DATE: June 25, 2004

    7 of 12 DOCUMENTS

    Copyright 2004 Drug Week via NewsRx.com & NewsRx.net
    Drug Week

    July 2, 2004

    SECTION: EXPANDED REPORTING; Pg. 104

    LENGTH: 234 words

    HEADLINE: CARDIOVASCULAR DISEASE;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Drug Week editors from staff and other reports.
    Copyright 2004, Drug Week via NewsRx.com & NewsRx.net.

    LOAD-DATE: June 25, 2004

    8 of 12 DOCUMENTS

    Copyright 2004 Biotech Week via NewsRx.com & NewsRx.net
    Biotech Week

    June 30, 2004

    SECTION: EXPANDED REPORTING; Pg. 109

    LENGTH: 235 words

    HEADLINE: CENTENARY INSTITUTE, NEWTOWN;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Biotech Week editors from staff and other
    reports. Copyright 2004, Biotech Week via NewsRx.com & NewsRx.net.

    LOAD-DATE: June 25, 2004

    9 of 12 DOCUMENTS

    Copyright 2004 Physician Law Weekly via LawRx.com via NewsRx.com and NewsRx.net
    Physician Law Weekly

    June 30, 2004

    SECTION: EXPANDED REPORTING; Pg. 77

    LENGTH: 235 words

    HEADLINE: CENTENARY INSTITUTE, NEWTOWN;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Physician Law Weekly editors from staff and
    other reports. Copyright 2004, Physician Law Weekly via LawRx.com.

    LOAD-DATE: June 25, 2004

    10 of 12 DOCUMENTS

    Copyright 2004 Cardiovascular Business Week via IncRx.com via NewsRx.com and
    NewsRx.net
    Cardiovascular Business Week

    June 29, 2004

    SECTION: EXPANDED REPORTING; Pg. 22

    LENGTH: 237 words

    HEADLINE: CENTENARY INSTITUTE, NEWTOWN;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Cardiovascular Business Week editors from staff
    and other reports. Copyright 2004, Cardiovascular Business Week via IncRx.com.

    LOAD-DATE: June 25, 2004

    11 of 12 DOCUMENTS

    Copyright 2004 Cardiovascular Week via NewsRx.com & NewsRx.net
    Cardiovascular Week

    June 28, 2004

    SECTION: EDITOR'S CHOICE; Pg. 2

    LENGTH: 237 words

    HEADLINE: CARDIOVASCULAR DISEASE;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Cardiovascular Week editors from staff and
    other reports. Copyright 2004, Cardiovascular Week via NewsRx.com &
    NewsRx.net.

    LOAD-DATE: June 25, 2004

    12 of 12 DOCUMENTS

    Copyright 2004 Health & Medicine Week via NewsRx.com & NewsRx.net
    Health & Medicine Week

    June 28, 2004

    SECTION: EXPANDED REPORTING; Pg. 180

    LENGTH: 239 words

    HEADLINE: CARDIOVASCULAR DISEASE;
    Implantable defibrillator effective against hypertrophic cardiomyopathy

    BODY:

    Implantable defibrillators reduce the long-term mortality risk in
    hypertrophic cardiomyopathy patients.

    In a recent study from Australia, "high-risk patients with hypertrophic
    cardiomyopathy were treated with an implantable defibrillator."

    "Long-term follow-up analysis showed the efficacy of implantable
    defibrillator therapy, with patients having an appropriate device intervention
    at a rate of 11%/year," reported I. Jayatilleke and coauthors working at the
    Centenary Institute.

    Implantable defibrillator treatment was responsible for "preventing sudden
    death in an Australian population," the researchers concluded.

    Jayatilleke and colleagues published their study in the American Journal of
    Cardiology (Long-term follow-up of implantable cardioverter defibrillator
    therapy for hypertrophic cardiomyopathy. Amer J Cardiol, 2004;93(9):1192-1194).

    For more information, contact I. Jayatilleke, Centenary Institute, Agnes
    Ginges Centre for Molecular Cardiology, Locked Bag 6, Newtown, NSW 2042,
    Australia.

    Publisher contact information for the American Journal of Cardiology is:
    Excerpta Medica Inc., 650 Avenue of the Americas, New York, NY 10011 USA.

    The information in this article comes under the major subject areas of
    Cardiovascular Disease and Medical Devices.

    This article was prepared by Health & Medicine Week editors from staff and
    other reports. Copyright 2004, Health & Medicine Week via NewsRx.com &
    NewsRx.net.

    LOAD-DATE: June 25, 2004
    ********** Email Completed **********
    Time of Delivery: June 25, 2004 03:40 PM EDT
    Email Number: 1862:1821780
    ***************************************
    Knowledge is power ... Stay informed!
    YOU can make a difference - all you have to do is try!

    Dx age 12 current age 46 and counting!
    lost: 5 family members to HCM (SCD, Stroke, CHF)
    Others diagnosed living with HCM (or gene +) include - daughter, niece, nephew, cousin, sister and many many friends!
    Therapy - ICD (implanted 97, 01, 04 and 11, medication
    Currently not obstructed
    Complications - unnecessary pacemaker and stroke (unrelated to each other)

Today's Birthdays

Collapse

Working...
X